{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:11:48Z","timestamp":1793293908805,"version":"4.5.0"},"reference-count":153,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["ZIA BC 011823"],"award-info":[{"award-number":["ZIA BC 011823"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jtct.2023.03.006","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T12:50:35Z","timestamp":1678366235000},"page":"438.e1-438.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":331,"title":["Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome"],"prefix":"10.1016","volume":"29","author":[{"given":"Melissa R.","family":"Hines","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7828-1522","authenticated-orcid":false,"given":"Tristan E.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-3569","authenticated-orcid":false,"given":"Kevin O.","family":"McNerney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-0221","authenticated-orcid":false,"given":"Mark B.","family":"Leick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6774-5694","authenticated-orcid":false,"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7665-7100","authenticated-orcid":false,"given":"Joshua A.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7789-1257","authenticated-orcid":false,"given":"Michael D.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris M.","family":"Mahadeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5247-5399","authenticated-orcid":false,"given":"Gabriela M.","family":"Maron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Nikiforow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda K.","family":"Ombrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4336-1071","authenticated-orcid":false,"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6558-6706","authenticated-orcid":false,"given":"Aimee C.","family":"Talleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0837-2688","authenticated-orcid":false,"given":"David","family":"Turicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-0490","authenticated-orcid":false,"given":"Anant","family":"Vatsayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy W.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna V.","family":"Komanduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Berliner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0629-2126","authenticated-orcid":false,"given":"Jan-Inge","family":"Henter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3688-9836","authenticated-orcid":false,"given":"Noelle V.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-8987","authenticated-orcid":false,"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.03.006_bib0001","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1182\/blood.2019000936","article-title":"Pediatric hemophagocytic lymphohistiocytosis","volume":"135","author":"Canna","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0002","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Rosee","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0003","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0004","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0005","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2023.03.006_bib0006","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0007","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1182\/bloodadvances.2021005020","article-title":"Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.03.006_bib0008","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0009","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0010","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.03.006_bib0011","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/08880018.2021.1988012","article-title":"Intravenous anakinra for tisagenlecleucel-related toxicities in children and young adults","volume":"39","author":"Dreyzin","year":"2022","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0012","doi-asserted-by":"crossref","first-page":"e05209","DOI":"10.1002\/ccr3.5209","article-title":"Hemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS) following treatment with tisagenlecleucel","volume":"10","author":"Martin-Rojas","year":"2022","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jtct.2023.03.006_bib0013","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.18454","article-title":"Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel","author":"Porter","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0014","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1080\/10428194.2021.1881507","article-title":"Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature","volume":"62","author":"Major","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2023.03.006_bib0015","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/bjh.16155","article-title":"Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy","volume":"187","author":"Hashmi","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0016","series-title":"ABECMA (idecabtagene vicleucel) package insert","year":"2021"},{"key":"10.1016\/j.jtct.2023.03.006_bib0017","unstructured":"US Food and Drug Administration. CARVYKTI (Ciltacabtagene autoleucel) package insert. Horsham, PA: Janssen Biotech, Inc; 2022."},{"key":"10.1016\/j.jtct.2023.03.006_bib0018","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood-2015-01-551622","article-title":"How I treat hemophagocytic lymphohistiocytosis in the adult patient","volume":"125","author":"Schram","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0019","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.15274","article-title":"How i treat primary haemophagocytic lymphohistiocytosis","volume":"182","author":"Marsh","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.coi.2017.08.004","article-title":"Hemophagocytic syndrome: primary forms and predisposing conditions","volume":"49","author":"Sepulveda","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0021","doi-asserted-by":"crossref","first-page":"e27929","DOI":"10.1002\/pbc.27929","article-title":"Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO)","volume":"66","author":"Jordan","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2023.03.006_bib0022","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis","volume":"118","author":"Jordan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0023","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/ng.3089","article-title":"An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome","volume":"46","author":"Canna","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtct.2023.03.006_bib0024","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/382262a0","article-title":"Identification of the homologous beige and Chediak-Higashi syndrome genes","volume":"382","author":"Barbosa","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2023.03.006_bib0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood-2017-11-814244","article-title":"Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis","volume":"132","author":"Chinn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0026","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/2424","article-title":"Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene","volume":"20","author":"Coffey","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtct.2023.03.006_bib0027","doi-asserted-by":"crossref","first-page":"13765","DOI":"10.1073\/pnas.95.23.13765","article-title":"Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome","volume":"95","author":"Nichols","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtct.2023.03.006_bib0028","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/26683","article-title":"The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM","volume":"395","author":"Sayos","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2023.03.006_bib0029","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1126\/science.286.5446.1957","article-title":"Perforin gene defects in familial hemophagocytic lymphohistiocytosis","volume":"286","author":"Stepp","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jtct.2023.03.006_bib0030","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/pbc.22830","article-title":"Hemophagocytic lymphohistiocytosis in children with chronic granulomatous disease","volume":"56","author":"Parekh","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2023.03.006_bib0031","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.mayocp.2013.12.012","article-title":"Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis","volume":"89","author":"Parikh","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jtct.2023.03.006_bib0032","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.amjmed.2014.04.034","article-title":"Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients","volume":"127","author":"Riviere","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0033","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2023.03.006_bib0034","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/BOR.0b013e32834dd37e","article-title":"Not all hemophagocytes are created equally: appreciating the heterogeneity of the hemophagocytic syndromes","volume":"24","author":"Canna","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0036","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2014-10-602607","article-title":"Marked hyperferritinemia does not predict for HLH in the adult population","volume":"125","author":"Schram","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0037","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(21)00366-5","article-title":"Malignancy-associated haemophagocytic lymphohistiocytosis","volume":"9","author":"Setiadi","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0038","doi-asserted-by":"crossref","first-page":"e874","DOI":"10.1097\/CCM.0000000000005038","article-title":"Diagnostic performance of hemophagocytic lymphohistiocytosis criteria and hscore in critically ill patients with severe hemophagocytic syndrome","volume":"49","author":"Valade","year":"2021","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0039","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s13054-020-02941-3","article-title":"Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore","volume":"24","author":"Knaak","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.jtct.2023.03.006_bib0040","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2010-01-265041","article-title":"Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0041","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0042","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2023.03.006_bib0043","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0044","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1158\/1078-0432.CCR-22-0822","article-title":"Comprehensive serum proteome profiling of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome patients with B-cell ALL receiving CAR T19","volume":"28","author":"Diorio","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2023.03.006_bib0045","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.03.006_bib0046","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0047","doi-asserted-by":"crossref","unstructured":"McNerney KO, Lim SS, Ishikawa K, et al. Chimeric antigen receptor T-cell-associated hemophagocytic lymphohistiocytosis (carHLH) predicts poor survival with real-world use of tisagenlecleucel for B-ALL. [preprints with the Lancet] July 27, 2022.","DOI":"10.2139\/ssrn.4172074"},{"key":"10.1016\/j.jtct.2023.03.006_bib0048","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0049","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1158\/1078-0432.CCR-20-1434","article-title":"Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"26","author":"Faramand","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2023.03.006_bib0050","article-title":"Poor clinical outcome in pediatric immunotherapy is mediated by a pre-existing overactive IL-18-IFNg immune phenotype","author":"Burleigh","year":"2021138","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0051","article-title":"Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel)","author":"Ahmed","year":"2020388057","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0052","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood.2021012764","article-title":"An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis","volume":"139","author":"Zoref-Lorenz","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0053","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","volume":"11","author":"Sandler","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0054","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/10428194.2021.2024817","article-title":"Low utility of the H-score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed\/refractory diffuse large B-cell lymphoma","volume":"63","author":"Kim","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2023.03.006_bib0055","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0056","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0057","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0058","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0059","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0060","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2023.03.006_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.845540","article-title":"Infectious complications in pediatric, adolescent and young adult patients undergoing CD19-CAR T cell therapy","volume":"12","author":"Maron","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0062","doi-asserted-by":"crossref","first-page":"e29247","DOI":"10.1002\/pbc.29247","article-title":"Consequences of hemophagocytic lymphohistiocytosis-like cytokine release syndrome toxicities and concurrent bacteremia","volume":"68","author":"Masih","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2023.03.006_bib0063","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1172\/JCI130059","article-title":"Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients","volume":"130","author":"Ishii","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2023.03.006_bib0064","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrclinonc.2018.20","article-title":"Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0065","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","article-title":"Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation","volume":"100","author":"Henter","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0066","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s10020-021-00308-0","article-title":"Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome","volume":"27","author":"Palmblad","year":"2021","journal-title":"Mol Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0067","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1111\/apa.15900","article-title":"Hyperinflammation: On the pathogenesis and treatment of macrophage activation syndrome","volume":"110","author":"Andersson","year":"2021","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.jtct.2023.03.006_bib0068","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4049\/jimmunol.1302282","article-title":"Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis","volume":"192","author":"Johnson","year":"2014","journal-title":"J Immunol"},{"issue":"S1","key":"10.1016\/j.jtct.2023.03.006_bib0069","doi-asserted-by":"crossref","first-page":"e30097","DOI":"10.1002\/pbc.30097","article-title":"Etoposide for Primary HLH- Better Than Its Reputation. Abstracts from the 38th Annual Meeting of the Histiocyte Society Held Virtually and In Person in Stockholm, Sweden from September 18-20, 2022","volume":"70","author":"Lehmberg","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2023.03.006_bib0070","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1182\/blood-2018-01-827485","article-title":"Treatment dilemmas in asymptomatic children with primary hemophagocytic lymphohistiocytosis","volume":"132","author":"Lucchini","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0071","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pbc.24188","article-title":"Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab","volume":"60","author":"Marsh","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2023.03.006_bib0072","article-title":"Alemtuzumab as first line treatment in children with familial lymphohistiocytosis","volume":"134","author":"Moshous","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0073","doi-asserted-by":"crossref","first-page":"e622","DOI":"10.1542\/peds.2006-3164","article-title":"Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients","volume":"120","author":"Mahlaoui","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.jtct.2023.03.006_bib0074","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1056\/NEJMc2020754","article-title":"Emapalumab in primary hemophagocytic lymphohistiocytosis","volume":"383","author":"Henter","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0075","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0076","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/CCM.0000000000005361","article-title":"Consensus-based guidelines for the recognition, diagnosis, and management of hemophagocytic lymphohistiocytosis in critically ill children and adults","volume":"50","author":"Hines","year":"2022","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0077","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.blre.2016.05.001","article-title":"Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review","volume":"30","author":"Hayden","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtct.2023.03.006_bib0078","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.13102","article-title":"Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide","volume":"168","author":"Arca","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0079","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/mpo.10314","article-title":"Treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in young adults: a report from the HLH study center","volume":"41","author":"Imashuku","year":"2003","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0080","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bjh.15988","article-title":"Requirement for etoposide in the initial treatment of Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis","volume":"186","author":"Song","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0081","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/pbc.24980","article-title":"Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children: report of the Japan Histiocytosis Study Group","volume":"61","author":"Kogawa","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2023.03.006_bib0082","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1080\/15384047.2021.1996139","article-title":"Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis","volume":"22","author":"Song","year":"2021","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jtct.2023.03.006_bib0083","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3899\/jrheum.200941","article-title":"Efficacy of moderately dosed etoposide in macrophage activation syndrome-hemophagocytic lymphohistiocytosis","volume":"48","author":"Horne","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0084","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/MD.0000000000000022","article-title":"Hemophagocytic lymphohistiocytosis: clinical analysis of 103 adult patients","volume":"93","author":"Li","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jtct.2023.03.006_bib0085","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2023.03.006_bib0086","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12969-021-00585-3","article-title":"Intravenous administration of anakinra in children with macrophage activation syndrome","volume":"19","author":"Phadke","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jtct.2023.03.006_bib0087","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.hoc.2015.06.010","article-title":"Macrophage activation syndrome","volume":"29","author":"Ravelli","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jtct.2023.03.006_bib0088","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1546-0096-12-13","article-title":"Treatment of juvenile idiopathic arthritis: a revolution in care","volume":"12","author":"Stoll","year":"2014","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jtct.2023.03.006_bib0089","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1097\/PCC.0000000000001827","article-title":"Outcomes analysis of children diagnosed with hemophagocytic lymphohistiocytosis in the PICU","volume":"20","author":"Gregory","year":"2019","journal-title":"Pediatr Crit Care Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0090","doi-asserted-by":"crossref","first-page":"e29102","DOI":"10.1002\/pbc.29102","article-title":"Continuous intravenous anakinra for treating severe secondary haemophagocytic lymphohistiocytosis\/macrophage activation syndrome in critically ill children","volume":"68","author":"Charlesworth","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2023.03.006_bib0091","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/0885066617711386","article-title":"Interleukin 1 receptor antagonist anakinra, intravenous immunoglobulin, and corticosteroids in the management of critically ill adult patients with hemophagocytic lymphohistiocytosis","volume":"34","author":"Wohlfarth","year":"2019","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0092","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1182\/blood.2022016421","article-title":"HLH treatment: smarter, not harder","volume":"139","author":"Henderson","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0093","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.2021014860","article-title":"A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis","volume":"139","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0094","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.3324\/haematol.2019.222471","article-title":"Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2023.03.006_bib0095","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjh.17331","article-title":"Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory\/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial","volume":"193","author":"Wang","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0096","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s13023-022-02516-1","article-title":"Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort study","volume":"17","author":"Kim","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jtct.2023.03.006_bib0097","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13054-020-02878-7","article-title":"IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome","volume":"24","author":"Dufranc","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.jtct.2023.03.006_bib0098","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.03.006_bib0099","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/blood-2021-146770","article-title":"Trials in progress: a two-cohort, open-label, single-arm study of emapalumab, an anti-interferon gamma (IFN\u03b3) monoclonal antibody, in patients with macrophage activation syndrome (MAS) in rheumatic diseases","volume":"138","author":"Grom","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0100","article-title":"Emapalumab, an Anti-IFN\u03b3 antibody in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA) who had failed high-dose glucocorticoids (GCs)","volume":"73","author":"De Benedetti","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0101","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.17673","article-title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"195","author":"Topp","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0102","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.03.006_bib0103","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood-2021-150431","article-title":"A phase II study of prophylactic anakinra to prevent CRS and neurotoxicity in patients receiving CD19 CAR T cell therapy for relapsed or refractory lymphoma","volume":"138","author":"Park","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2023.03.006_bib0104","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2023.03.006_bib0105","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0106","doi-asserted-by":"crossref","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0107","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2023.03.006_bib0108","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.bbmt.2019.04.003","article-title":"Efficacy, toxicity, and infectious complications in ruxolitinib-treated patients with corticosteroid-refractory graft-versus-host disease after hematopoietic cell transplantation","volume":"25","author":"Abedin","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.03.006_bib0109","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0110","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.03.006_bib0111","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/BF02984009","article-title":"Encouraging results of low-dose etoposide in the treatment of early-onset hemophagocytic syndrome following allogeneic hematopoietic stem cell transplantation","volume":"86","author":"Koyama","year":"2007","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0112","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study","volume":"130","author":"Bergsten","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0113","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261","article-title":"Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol","volume":"118","author":"Trottestam","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0114","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.jaip.2018.05.031","article-title":"Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: Consensus statements by the HLH Steering Committee of the Histiocyte Society","volume":"6","author":"Ehl","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jtct.2023.03.006_bib0115","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF02982023","article-title":"Risk of etoposide-related acute myeloid leukemia in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis","volume":"75","author":"Imashuku","year":"2002","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0116","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJM199112123252402","article-title":"Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia","volume":"325","author":"Pui","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0117","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1159\/000525576","article-title":"Dramatic recovery after etoposide phosphate infusion for hemophagocytic lymphohistiocytosis\/macrophage activation syndrome following treatment with tisagenlecleucel in a young patient with relapsed acute lymphoblastic leukemia: A case report","volume":"145","author":"Peterlin","year":"2022","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0118","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1016\/S2666-6367(22)00359-1","article-title":"Proinflammatory cytokines are associated with CAR-22 macrophage activation syndrome","volume":"28","author":"Srinagesh","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.03.006_bib0119","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFNgamma reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jtct.2023.03.006_bib0120","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-21-0203","article-title":"Potential role of IFNgamma inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy","volume":"3","author":"McNerney","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jtct.2023.03.006_bib0121","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T cell killing requires the IFNgammaR pathway in solid but not liquid tumours","volume":"604","author":"Larson","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2023.03.006_bib0122","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/jnci\/djz017","article-title":"CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions","volume":"111","author":"Hunter","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtct.2023.03.006_bib0123","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0124","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","article-title":"Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"76","author":"Bracaglia","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtct.2023.03.006_bib0125","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jpeds.2011.11.046","article-title":"Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children","volume":"160","author":"Xu","year":"2012","journal-title":"J Pediatr"},{"key":"10.1016\/j.jtct.2023.03.006_bib0126","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.V78.11.2918.2918","article-title":"Hypercytokinemia in familial hemophagocytic lymphohistiocytosis","volume":"78","author":"Henter","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0127","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jtct.2023.03.006_bib0128","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0129","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1473-3099(07)70290-6","article-title":"Infections associated with haemophagocytic syndrome","volume":"7","author":"Rouphael","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jtct.2023.03.006_bib0130","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00277-013-1878-y","article-title":"IP-10\/CXCL10 and MIG\/CXCL9 as novel markers for the diagnosis of lymphoma-associated hemophagocytic syndrome","volume":"93","author":"Maruoka","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0131","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00277-013-1819-9","article-title":"Recombinant human thrombopoietin is an effective treatment for thrombocytopenia in hemophagocytic lymphohistiocytosis","volume":"92","author":"Wang","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0132","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11684-013-0292-0","article-title":"Hemophagocytic lymphohistiocytosis: critical reappraisal of a potentially under-recognized condition","volume":"7","author":"Padhi","year":"2013","journal-title":"Front Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0133","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/ajh.20202","article-title":"Hemophagocytosis exacerbated by G-CSF\/GM-CSF treatment in a patient with myelodysplasia","volume":"77","author":"Wang","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0134","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-022-00741-2","article-title":"Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma","volume":"12","author":"Miller","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2023.03.006_bib0135","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/s41409-020-01006-x","article-title":"G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory\/relapsed B-cell lymphoma","volume":"55","author":"Galli","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.03.006_bib0136","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1111\/trf.17071","article-title":"Allogeneic CD34-selected stem cell boost as salvage treatment of life-threatening infection and severe cytopenias after CAR-T cell therapy","volume":"62","author":"de Tena","year":"2022","journal-title":"Transfusion"},{"key":"10.1016\/j.jtct.2023.03.006_bib0137","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1182\/bloodadvances.2022007776","article-title":"Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy","volume":"6","author":"Rejeski","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.03.006_bib0138","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1182\/bloodadvances.2022007572","article-title":"CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy","volume":"6","author":"Mullanfiroze","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.03.006_bib0139","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251216","article-title":"Coagulation disorders in patients with severe hemophagocytic lymphohistiocytosis","volume":"16","author":"Valade","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jtct.2023.03.006_bib0140","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/bloodadvances.2020002757","article-title":"Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy","volume":"5","author":"Buechner","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.03.006_bib0141","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/08830738211009654","article-title":"Exploring the intersection of isolated-CNS hemophagocytic lymphohistiocytosis and pediatric chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids","volume":"36","author":"Debinski","year":"2021","journal-title":"J Child Neurol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0142","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s10875-020-00814-6","article-title":"Neuroinflammatory disease as an isolated manifestation of hemophagocytic lymphohistiocytosis","volume":"40","author":"Blincoe","year":"2020","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0143","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtct.2023.03.006_bib0144","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.03.006_bib0145","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1182\/blood-2021-149501","article-title":"CAR-T Toxicity management and steroid use in high-grade B-cell lymphoma: impact on real-world survival outcomes in the UK","volume":"138","author":"Sanderson","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.006_bib0146","series-title":"StatPearls Publishing [Internet]","author":"Haq","year":"2023"},{"key":"10.1016\/j.jtct.2023.03.006_bib0147","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00134-019-05884-8","article-title":"Transfusion strategies in non-bleeding critically ill adults: a clinical practice guideline from the European Society of Intensive Care Medicine","volume":"46","author":"Vlaar","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0148","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa066240","article-title":"Transfusion strategies for patients in pediatric intensive care units","volume":"356","author":"Lacroix","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.03.006_bib0149","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.03.006_bib0150","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/bloodadvances.2022006983","article-title":"Anakinra utilization in refractory pediatric CAR T-cell associated toxicities","volume":"6","author":"Diorio","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.03.006_bib0151","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamaoncol.2022.0070","article-title":"Use of early intrathecal therapy to manage high-grade immune effector cell-associated neurotoxicity syndrome","volume":"8","author":"Zurko","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2023.03.006_bib0152","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","article-title":"American Society for Transplantation and Cellular Therapy Series. No.3 Prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation","volume":"27","author":"Hakki","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.03.006_bib0153","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jtct.2020.10.003","article-title":"American Society of Transplantation and Cellular Therapy Series. No.2 Management and prevention of aspergillosis in hematopoietic cell transplantation recipients","volume":"27","author":"Dadwal","year":"2021","journal-title":"Transplant Cell Ther"}],"updated-by":[{"DOI":"10.1016\/j.jtct.2025.09.016","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000}}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723011648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723011648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:10:04Z","timestamp":1763003404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723011648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":153,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2666636723011648"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.03.006","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}